Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.47 |
| ▸ | ADK | P55263 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3822608 | 0.86 | DYRK3 (0.46) | HSP90AA1HSP90AB1ADKKDM4EPDE5A | |
| SCHEMBL18342054 | 0.77 | MEN1 (0.51) | ADKMEN1KMT2ASLC29A1 | |
| SCHEMBL3396153 | 0.77 | HSP90AA1 (0.69) | HSP90AA1HSP90AB1KDM4EMEN1KMT2A | |
| SCHEMBL16235957 | 0.76 | ADK (0.40) | ADKKDM4EMEN1KMT2ASLC29A1 | |
| SCHEMBL29503417 | 0.73 | ADK (0.46) | ADKMEN1KMT2ASLC29A1 | |
| SCHEMBL16236999 | 0.73 | ADK (0.46) | ADKMEN1KMT2ASLC29A1 | |
| SCHEMBL16236547 | 0.73 | ADK (0.47) | ADKMEN1KMT2ASLC29A1 | |
| SCHEMBL23630551 | 0.71 | ADK (0.43) | ADKMEN1KMT2ASLC29A1 | |
| SCHEMBL16236531 | 0.71 | ADK (0.44) | ADKMEN1KMT2ASLC29A1 | |
| SCHEMBL16236981 | 0.71 | KDM4C (0.41) | ADKMEN1ALDH1A1KMT2ASLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730148-A4 | AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS | ABBOTT LAB (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-1730148-A2 | AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS | Abbott Laboratories (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20060025383-A1 | Aminobenzoxazoles as therapeutic agents | ABBOTT LABORATORIES | 2006-02-02 | — | — | US | disclosed |
| WO-2005074603-A2 | AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025383-A1 | Aminobenzoxazoles as therapeutic agents | ABL1, MAP3K19, MAP3K20 | HSP90AA1 1875/4885HSP90AB1 1273/4885ADK 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.